Literature DB >> 34480941

Opioid-Free Discharge is Not Associated With Increased Unplanned Healthcare Encounters After Ureteroscopy: Results From a Statewide Quality Improvement Collaborative.

Scott R Hawken1, Spencer C Hiller1, Stephanie Daignault-Newton1, Khurshid R Ghani1, John M Hollingsworth1, Bronson Conrado1, Conrad Maitland2, David L Wenzler3, John K Ludlow4, Sapan N Ambani1, Chad M Brummett5, Casey A Dauw6.   

Abstract

OBJECTIVES: To evaluate patient factors associated with post-ureteroscopy opioid prescriptions, provider-level variation in opioid prescribing, and the relationship between opioid-free discharges and ED visits.
METHODS: This is a retrospective analysis of a prospective cohort study of adults age 18 years and older who underwent primary ureteroscopy for urinary stones from June 2016 to September 2019 within the Michigan Urological Surgery Improvement Collaborative (MUSIC) Reducing Operative Complications from Kidney Stones (ROCKS) quality improvement initiative. Postoperative opioid prescription trends and variation among practices and surgeons were examined. Multivariable logistic regression models defined risk factors for receipt of opioid prescriptions. The association among opioid prescriptions and postoperative ED visits within 30 days of surgery was assessed among complete case and propensity matched cohorts, matched on all measured characteristics other than opioid receipt.
RESULTS: 13,143 patients underwent ureteroscopy with 157 urologists across 28 practices. Post-ureteroscopy opioid prescriptions and ED visits declined (86% to 39%, P<.001; 10% to 6%, P<.001, respectively). Practice and surgeon-level opioid prescribing varied from 8% to 98%, and 0% to 98%, respectively. Patient-related factors associated with opioid receipt included male, younger age, and history of chronic pain. Procedure-related factors associated with opioid receipt included pre- and post-ureteroscopy ureteral stenting and access sheath use. An opioid-free discharge was not associated with increased odds of an ED visit (OR 0.77, 95% CI 0.62-0.95, P=.014).
CONCLUSIONS: There was no increase in ED utilization among those not prescribed an opioid after ureteroscopy, suggesting their routine use may not be necessary in this setting.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34480941      PMCID: PMC8671211          DOI: 10.1016/j.urology.2021.07.037

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  24 in total

1.  Changing Trends in the Treatment of Nephrolithiasis in the Real World.

Authors:  Kyung Jin Chung; Jae Heon Kim; Gyeong Eun Min; Hyoung Keun Park; Shufeng Li; Francesco Del Giudice; Deok Hyun Han; Benjamin I Chung
Journal:  J Endourol       Date:  2019-02-13       Impact factor: 2.942

2.  Enhanced Recovery After Surgery Protocol for Patients Undergoing Ureteroscopy: Prospective Evaluation of an Opioid-Free Protocol.

Authors:  Chad Gridley; Jennifer Robles; Joshua Calvert; Nicholas Kavoussi; Taylor Winkler; Jennifer Jayaram; Matthew Fosnot; Justin Liberman; Brian Allen; Matthew McEvoy; Duke Herrell; Ryan Hsi; Nicole L Miller
Journal:  J Endourol       Date:  2020-02-28       Impact factor: 2.942

3.  Wide Variation in Opioid Prescribing After Urological Surgery in Tertiary Care Centers.

Authors:  Matthew J Ziegelmann; Jason P Joseph; Amy E Glasgow; Mark D Tyson; Raymond W Pak; Halena M Gazelka; Ashton L Schatz; Bradley C Leibovich; Elizabeth B Habermann; Matthew T Gettman
Journal:  Mayo Clin Proc       Date:  2019-02       Impact factor: 7.616

4.  National Variation in Opioid Prescription Fills and Long-Term Use in Opioid Naïve Patients after Urological Surgery.

Authors:  Ian Berger; Marshall Strother; Ruchika Talwar; Justin Ziemba; Christopher Wirtalla; Leilei Xia; Thomas Guzzo; M Kit Delgado; Rachel Kelz
Journal:  J Urol       Date:  2019-10-09       Impact factor: 7.450

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Shockwave Lithotripsy Use in the State of Michigan: American Urological Association Guideline Adherence and Clinical Implications.

Authors:  Casey A Dauw; Kavya Swarna; Ji Qi; Tae Kim; David Leavitt; Joshua Leese; Mazen Abdelhady; Karla Witzke; John M Hollingsworth; Khurshid R Ghani
Journal:  Urology       Date:  2019-12-13       Impact factor: 2.649

7.  Wide Variation and Overprescription of Opioids After Elective Surgery.

Authors:  Cornelius A Thiels; Stephanie S Anderson; Daniel S Ubl; Kristine T Hanson; Whitney J Bergquist; Richard J Gray; Halena M Gazelka; Robert R Cima; Elizabeth B Habermann
Journal:  Ann Surg       Date:  2017-10       Impact factor: 12.969

8.  Unplanned 30-Day Encounters After Ureterorenoscopy for Urolithiasis.

Authors:  Kefu Du; Robert S Wang; Joel Vetter; Alethea G Paradis; Robert S Figenshau; Ramakrishna Venkatesh; Alana C Desai
Journal:  J Endourol       Date:  2018-10-18       Impact factor: 2.942

9.  Decrease in Urologic Discharge Opioid Prescribing after Mandatory Query of Statewide Prescription Drug Monitoring Program.

Authors:  John M Myrga; Liam C Macleod; Jathin Bandari; Bruce L Jacobs; Benjamin J Davies
Journal:  Urology       Date:  2020-02-13       Impact factor: 2.649

10.  Opioid Prescribing to Medicare Part D Enrollees, 2013-2017: Shifting Responsibility to Pain Management Providers.

Authors:  Adam N Romman; Connie M Hsu; Lin-Na Chou; Yong-Fang Kuo; Rene Przkora; Rajnish K Gupta; M James Lozada
Journal:  Pain Med       Date:  2020-11-07       Impact factor: 3.637

View more
  1 in total

Review 1.  Ureteral Access Sheaths and Its Use in the Future: A Comprehensive Update Based on a Literature Review.

Authors:  Vincent De Coninck; Bhaskar Somani; Emre Tarik Sener; Esteban Emiliani; Mariela Corrales; Patrick Juliebø-Jones; Amelia Pietropaolo; Ioannis Mykoniatis; Belthangady M Zeeshan Hameed; Francesco Esperto; Silvia Proietti; Olivier Traxer; Etienne Xavier Keller
Journal:  J Clin Med       Date:  2022-08-31       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.